-
Rare mountain gorilla twins born in DR Congo: park authorities
-
Ex-midwife enthroned as first female Archbishop of Canterbury
-
AC Schnitzer: When Iconic Tuners Fall Silent
-
Senegal lodge appeal to Court of Arbitration for Sport over AFCON final decision
-
South Africa seal T20 series win in New Zealand
-
Study links major polluters to big climate damages bill
-
Ex-Google chief Matt Brittin made new BBC director-general
-
Iran likely behind attacks sowing fear among Europe's Jews: experts
-
'Relieved' McGrath claims career first crystal globe in slalom
-
US ski star Shiffrin wins overall World Cup title for sixth time
-
Trump names tech titans to science advisory council
-
Mideast war sparks long queues at Kinshasa petrol stations
-
US TV star details 'agony' over mother's disappearance
-
Tehran receives US plan to end Mideast war, as Iran fires at US carrier
-
Aviation, tourism, agriculture... the economic sectors hit by the war
-
Iran fires at US carrier as backchannel diplomacy aims to end war
-
Salah's long goodbye brings curtain down on golden era for Liverpool
-
Monaco: city of vice and a few virtues
-
AI making cyber attacks costlier and more effective: Munich Re
-
Defying Israeli bombs, Lebanese hold out in southern city of Tyre
-
War-linked power crunch pushes Sri Lanka to four-day week
-
Hungary says will phase out gas deliveries to Ukraine
-
Oil prices tumble, stocks rally on Mideast peace hopes
-
Maybach: Between Glory and a Turning Point
-
German business morale falls as war puts recovery on ice: survey
-
Labubu maker Pop Mart's shares fall 23% despite surging earnings
-
ECB won't be 'paralysed' in face of energy shock: Lagarde
-
Iran hits targets across Middle East after Trump signals talks progress
-
McEvoy says best is to come after breaking long-standing swim record
-
Goat vs gecko: A tiny Caribbean island faces wildlife showdown
-
Japan PM asks IEA chief to prepare additional 'coordinated release' of oil
-
Hungary's hard-pressed LGBTQ people say Orban exit is only half battle
-
Belarus leader visits North Korea for first time
-
'No heavier burden': the decades-long search for Kosovo war missing
-
Exotic pet trade thrives in China despite welfare concerns
-
Iran fires missile salvo after Trump signals progress in talks
-
BTS concert drew 18.4 million viewers, says Netflix
-
OSCE's 'chaotic' Ukraine evacuation put staff at risk: leaked report
-
Top WTO official sounds fertiliser warning over Middle East war
-
France and Brazil weigh up World Cup prospects in glamour friendly
-
Italy hoping to end World Cup pain as play-offs loom
-
Dirty diapers born again in Japan recycling breakthrough
-
Verstappen's Japan GP win streak under threat as Mercedes dominate
-
Crude tumbles, stocks rally on hopes for Iran war de-escalation
-
Gauff outlasts Bencic to reach Miami semi-finals
-
'Hero' Australian dog who saved 100 koalas retires
-
Underdogs chase World Cup berths in Mexico playoff tournament
-
Pope heads to tiny Catholic Monaco
-
Meet the four astronauts set to voyage around the Moon
-
Artemis 2 Moon mission: a primer
Trump announces Pfizer deal he says will lower certain drug prices
The Trump administration on Tuesday announced a deal granting Pfizer a three-year reprieve on planned tariffs as the pharmaceutical giant vowed to voluntarily lower the prices of unspecified drugs for US purchase.
President Donald Trump, flanked by top health officials, was scant on details regarding what or how many drugs were included in the agreement, the announcement of which came as Washington faced a looming government shutdown.
Under the deal Pfizer is to charge "Most Favored Nation" pricing -- matching the lowest price offered in other wealthy nations -- to Medicaid, the US health insurance program for low-income Americans.
The White House also said it would unveil a website -- called TrumpRx -- that would allow consumers to directly purchase some medications from manufacturers at discounted rates.
Like Trump, Pfizer CEO Albert Bourla heralded the deal as a great achievement, although a statement from the company was equally vague on specifics.
The company did say a "large majority" of "primary care treatments and some select specialty brands" could be offered at savings from 50 percent to 85 percent.
"We now have the certainty and stability we need on two critical fronts, tariffs and pricing, that have suppressed the industry's valuations to historic lows," said Bourla.
Part of the deal included Pfizer agreeing to "invest $70 billion to reshore domestic manufacturing facilities" to the United States.
- Wider impact unclear -
Trump's initiative revives drug-pricing efforts from his first term. The president has taken steps since returning to the White House to pressure pharmaceutical companies into voluntarily lowering their prices.
In July the US leader sent letters to leading pharmaceutical companies demanding they lower drug prices.
Democrats have long indicated that they, too, would like to lower drug prices.
In a report released Monday, independent Senator Bernie Sanders said that Trump's efforts on the issue had "made headlines" but had done "little beyond that."
The member of the Senate's health committee said in his report that since Trump sent the letters over the summer, the prices of 87 drugs actually increased.
Drug costs for consumers in the United States can depend on several variables, notably insurance coverage.
Many people receive insurance through an employer, the health insurance market or government programs including Medicare, which is for seniors, and the safety net Medicaid.
It is not clear how Tuesday's deal will impact drug pricing in the commercial insurance market.
The announcement comes as drugmakers gird for a 100-percent tariff Trump said he would impose on branded pharmaceutical products entering the country from October 1 -- unless companies were building manufacturing plants in the United States.
But details surrounding the rollout remain unclear.
Since returning to the presidency in January, Trump has imposed sector-specific tariffs on imports like steel, aluminum and autos, while launching investigations into other areas like pharmaceuticals that could lead to new levies.
Asked Tuesday about the timeline for fresh tariffs, Commerce Secretary Howard Lutnick said the Trump administration plans to allow negotiations with companies to play out.
J.Williams--AMWN